Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial. (23rd September 2022)

• Record Type: Journal Article
• Authors: Wang, Shumin; Zhang, Meiyi; Yu, Leilei; Tian, Fengwei; Lu, Wenwei; Wang, Gang; Chen, Wei; Wang, Jialin; Zhai, Qixiao
• Other Names: Chen Tingtao Academic Editor.
• Is Part Of: Canadian journal of infectious diseases & medical microbiology =. Volume 2022(2022)
• Publication Date: 2022-09-23
• Subjects: Communicable diseases -- Periodicals; Infection -- Periodicals; Communicable diseases; Infection; Communicable Diseases; Communicable Disease Control; Electronic journals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.9
• DOI: 10.1155/2022/6432750
• Languages: English
• ISSNs: 1712-9532

Abstract

Abstract : Background . The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear. Aim . To evaluate the accuracy and efficacy of specific Lactobacillus strains against H. pylori infection. Methods . Seventy-eight patients with H. pylori infection were treated with strain L. crispatus G14-5M ( L. crispatus CCFM1118) or L. helveticus M2-09-R02-S146 ( L. helveticus CCFM1121) or L. plantarum CCFM8610 at a dose of 2 g twice daily for one month. 14 C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the Lactobacillus strains in eradicating H. pylori infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial. Results . The 14 C-urea breath test value of the three Lactobacillus treatment groups had decreased significantly, and the eradication rate of H. pylori had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, P = 0.0039 ), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate H. pylori infection. The ingestion of Lactobacillus strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of H. pylori -infected patients appeared to modulate the gut microbiota of patients. However, none of the Lactobacillus strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor α concentrations, or serum pepsinogen concentrations in the patients. Conclusion . Three Lactobacillus strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of H. pylori -infected patients. The activity of probiotics in eradicating H. pylori infection may be species/strain specific.